SEC Form 4 · accession 0001140361-17-013319
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — President, Worldwide R&D
Period of report
Mar 22, 2017
Accepted (ET)
Mar 24, 2017 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 22, 2017 | A | 19,790 | $0.00 | A | 140,192 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F2 | $87.42 | Mar 22, 2017 | A | 64,030 | A | Mar 22, 2018 | Mar 21, 2027 | Common Stock | 64,030 | 64,030 | D |
Explanation of responses
- F1Restricted stock units granted on March 22, 2017. Price not applicable.
- F2Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter.